BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8857072)

  • 1. Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline.
    Korn A; Wagner B; Moritz E; Dingemanse J
    Eur J Clin Pharmacol; 1996; 49(4):273-8. PubMed ID: 8857072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyramine pharmacodynamics during combined administration of lazabemide and moclobemide.
    Dingemanse J; Hussain Y; Korn A
    Int J Clin Pharmacol Ther; 1996 Apr; 34(4):172-7. PubMed ID: 8861736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers.
    Berlin I; Zimmer R; Cournot A; Payan C; Pedarriosse AM; Puech AJ
    Clin Pharmacol Ther; 1989 Sep; 46(3):344-51. PubMed ID: 2673623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects.
    Dingemanse J; Wood N; Guentert T; Oie S; Ouwerkerk M; Amrein R
    Psychopharmacology (Berl); 1998 Nov; 140(2):164-72. PubMed ID: 9860107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
    Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
    Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between moclobemide and oral tyramine in depressed patients.
    Burgess CD; Mellsop GW
    Fundam Clin Pharmacol; 1989; 3(1):47-52. PubMed ID: 2714732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyramine pressor response with moclobemide--a reversible monoamine oxidase inhibitor.
    Tiller JW; Maguire KP; Davies BM
    Psychiatry Res; 1987 Nov; 22(3):213-20. PubMed ID: 3432450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline.
    Dingemanse J; Kneer J; Wallnöfer A; Kettler R; Zürcher G; Koulu M; Korn A
    Clin Neuropharmacol; 1996 Oct; 19(5):399-414. PubMed ID: 8889283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.
    Cusson JR; Goldenberg E; Larochelle P
    J Clin Pharmacol; 1991 May; 31(5):462-7. PubMed ID: 2050833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers.
    Simpson GM; Gratz SS
    Clin Pharmacol Ther; 1992 Sep; 52(3):286-91. PubMed ID: 1526086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor.
    Korn A; Da Prada M; Raffesberg W; Allen S; Gasic S
    J Neural Transm Suppl; 1988; 26():57-71. PubMed ID: 3162952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects.
    Azzaro AJ; Vandenberg CM; Blob LF; Kemper EM; Sharoky M; Oren DA; Campbell BJ
    J Clin Pharmacol; 2006 Aug; 46(8):933-44. PubMed ID: 16855078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males.
    Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; Darnow J; Azzaro AJ; DiSanto AR
    J Clin Pharmacol; 1997 Mar; 37(3):238-47. PubMed ID: 9089426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine.
    Korn A; Da Prada M; Raffesberg W; Gasic S; Eichler HG
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):17-23. PubMed ID: 2450251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of the pressor effect of intravenously administered tyramine during moclobemide treatment.
    Zimmer R; Fischbach R; Breuel HP
    Acta Psychiatr Scand Suppl; 1990; 360():76-7. PubMed ID: 2248082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
    Zimmer R
    Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine.
    Gieschke R; Schmid-Burgk W; Amrein R
    J Neural Transm Suppl; 1988; 26():97-104. PubMed ID: 3283292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.
    Schulz R; Antonin KH; Hoffmann E; Jedrychowski M; Nilsson E; Schick C; Bieck PR
    Clin Pharmacol Ther; 1989 Nov; 46(5):528-36. PubMed ID: 2510962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
    Clarke A; Johnson ES; Mallard N; Corn TH; Johnston A; Boyce M; Warrington S; MacMahon DG
    J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hypertensive crises with reversible inhibitors of monoamine oxidases? Results of tyramine interaction studies].
    Bieck PR
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():25-31. PubMed ID: 2587674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.